Information Provided By: 
Fly News Breaks for October 24, 2019
BIIB, ESALY
Oct 24, 2019 | 06:47 EDT
Nomura Instinet analyst Motoya Kohtani upgraded Eisai (ESALY) to Buy from Neutral with a price target of 15,000 yen, up from 5,500 yen. The company's development partner Biogen (BIIB) announced that it plans to pursue regulatory approval for Alzheimer's disease treatment aducanumab in the U.S. following consultation with the FDA, Kohtani tells investors in a research note. The analyst thinks aducanumab is now more likely to become the world's first Alzheimer's disease modifying agent.
News For ESALY;BIIB From the Last 2 Days
BIIB
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 13:04 EDT
BIIB
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 06:50 EDT
BIIB
Apr 24, 2024 | 06:48 EDT
